Haemonetics (NYSE: HAE) announced today that it acquired percutaneous vessel closure device maker Vivasure Medical.

Orchestra BioMed (Nasdaq:OBIO) expects to receive up to $21 million in cash as a result of Haemonetics' recent.

Haemonetics will shell out up to 185 million euros ($216 million) to acquire Vivasure Medical, a Galway, Ireland-based medtech that makes arterial closure devices.

Haemonetics (HAE) to acquire Vivasure Medical Limited for 100 million euros upfront plus potential milestone payments.

Investors may be wondering whether Haemonetics at around US$74 is offering value right now, or whether the market is still ...

Haemonetics has acquired Vivasure, an Ireland-based company developing next-generation technology for percutaneous vessel ...

Analysts have recently evaluated Haemonetics and provided 12-month price targets. The average target is $87.45, accompanied ...

The purchase is expected to expand Haemonetics’ impact in fast-growing markets for structural heart and endovascular ...

Blood products company Haemonetics (NYSE:HAE). reported in Q3 CY2025, but sales fell by 5.3% year on year to $327.3 million. Its non-GAAP profit of $1.27 per share was 14.3% above analysts’ consensus ...

Haemonetics (HAE) has an impressive earnings surprise history and currently possesses the right combination of the two key ...

BOSTON, June 18, 2024 /PRNewswire/ -- Haemonetics Corporation (HAE), a global medical technology company focused on delivering innovative solutions to drive better patient outcomes, has launched a ...

BOSTON, Nov. 6, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its second quarter fiscal year 2026, which ended September 27, 2025, are available on the ...